Facts cited from the ClinicalTrials.gov record NCT07137767 (last update posted 18 November 2026), verified 18 November 2026. General information, not legal or regulatory advice. Confirm current ANVISA, CEP/CONEP, and FDA rules with qualified advisers. We name only the facility, investigator, sponsor, and design the registry lists. TECLens, Inc. is not claimed as a bioaccess® client.
If you searched Rio Vision Hospital Oftalmológico, Dr. Renato Ambrósio Jr. clinical trial, TECLens Brazil, corneal crosslinking feasibility study Rio de Janeiro, or “go direct to the eye hospital in Rio,” you followed a facility and investigator name that a public registry record put into the open. The hospital and its principal investigator are a real, named site. They are not the operator of the first-in-human or early-feasibility file.
bioaccess®’s position is simple and it is not adversarial: the investigator and the hospital are the site. The First-in-Human CRO still owns the ANVISA device clinical-trial file, CEP/CONEP ethics review, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country.
What the public record says
ClinicalTrials.gov record NCT07137767, “Quantitative Refractive Crosslinking in Adults and Presbyopia-Aged Patients,” is sponsored by TECLens, Inc. (industry). The registry describes a single-arm, open-label feasibility study of the TECLens CXLens Crosslinking System: one eye per participant receives riboflavin drops and low-energy ultraviolet light delivered through a special contact lens, aiming to reduce nearsightedness or farsightedness in adults aged 25 to 75. The first 3 to 5 participants are followed through the 1-month visit before the rest enroll. Estimated enrollment is 25; the record shows an actual start of 22 January 2026 and status Recruiting.
The record lists two recruiting sites:
- Rio Vision Hospital Oftalmológico, Rio de Janeiro, Brazil — principal investigator Renato Ambrósio Jr., MD, PhD.
- Laser Center, Santo Domingo, Dominican Republic — principal investigator Juan F. Batlle, MD. That facility has its own page: Laser Center Santo Domingo first-in-human.
The record names no collaborator and no CRO. It reports no results.
A named eye hospital is a site. The CRO is the operator.
A high-volume refractive and corneal center in Rio de Janeiro can provide the surgeon, the patients, the imaging, and the follow-up visits. That is necessary. It is not sufficient for an investigational device study whose data a U.S. board and the FDA may later read.
- ANVISA and CEP/CONEP. The national device clinical-trial file and the ethics pathway are their own workstream — see the ANVISA device clinical trial submission guide.
- Investigational import of the light source, lenses, and drug-device components — see importer of record for clinical trial devices in Latin America.
- Staggered enrollment and safety review. A sentinel cohort held at 1 month needs a documented go/no-go decision, not an email thread.
- ISO 14155 monitoring, EDC, adverse-event reporting, and the TMF across two countries.
- The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review when the study meets that rule’s GCP and ethics documentation. Eligibility is not clearance.
For how ophthalmic first-in-human sponsors weigh going direct to a clinic against a CRO, see ophthalmic FIH clinics in Latin America vs. a CRO and early feasibility studies in Latin America vs. the US.
What is not claimed here
- That bioaccess® runs, monitors, or has any role in NCT07137767, or that TECLens is a bioaccess® client.
- Any outcome data; the registry reports none.
- Anything about Dr. Ambrósio or the hospital beyond what the registry record lists.
Frequently asked questions
Can I contract Rio Vision Hospital Oftalmológico or Dr. Ambrósio directly for my device?
You can ask. A hospital and its investigator can discuss interest and feasibility. They cannot become your ANVISA applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager by being listed on a registry.
Is this the same page as Laser Center in Santo Domingo?
No. The second site on the same study has its own page: Laser Center Santo Domingo first-in-human. This page answers the Rio de Janeiro facility and investigator query. For the country view, see CRO in Brazil.
Does bioaccess® still run trials in Colombia?
Yes. bioaccess® still runs clinical trials in Colombia, alongside Brazil, Panama, and the rest of the platform.
Next step
If the search that brought you here was Rio Vision Hospital Oftalmológico, Dr. Renato Ambrósio Jr., TECLens, or corneal crosslinking studies in Brazil, start with the operator: contact bioaccess® or see First-in-Human CRO.